Cerebral executives told its clinicians that the company will pause prescribing controlled substances like Adderall to treat attention deficit hyperactivity disorder in new patients beginning Monday, the company said.
Cerebral’s co-founder and Chief Executive Kyle Robertson made the announcement in an email sent to staff this week, adding that the company will continue to treat existing ADHD patients.
To Read the Full Story
This post first appeared on wsj.com
